September 2024 Activities Report and Appendix 4C

Key points:

- **PTX-100 will focus on cutaneous T cell lymphoma (CTCL) for Phase 2 clinical trial**
- **Prescient to focus on CTCL for Phase 2, which presents a more efficient pathway towards approval, whilst continuing to treat PTCL patients under the existing Phase 1b protocol**
- **CellPryme data presented and well received at CAR-TCR Summit in Boston, with positive reception from industry**
- **Discussions with CellPryme-M parties progressing in parallel**
- **Cash and term deposit balance of $11.5 million with spending in line with budget**

MELBOURNE Australia, 31 October 2024: Prescient Therapeutics (ASX: PTX), a clinical stage oncology company developing personalised therapies for cancer, today reported its Appendix 4C quarterly cash flow statement and accompanying Activities Report for the September 2024 quarter.

Financial summary

Prescient ended the quarter with cash reserves of $11.5 million ($14.5 million on 30 June 2024) of which $4.0 million was held in term deposits with maturities greater than three months. Net operating expenditure during the quarter was $2.8 million, in line with budget. A total of $1.8 million was invested in R&D and clinical development activities.

The business is operating with a cash runway of 4.1 quarters based on net cash used during the quarter, however, expenditure is expected to increase later this year commensurate with an increase in clinical trial activities. Payments to related parties of the entity and their associates amounted to $194,000 and were directly related to non-executive director fees, executive director salary and superannuation.

PTX-100 activity summary

Prescient has been deeply immersed in preparatory activities pertaining to the Phase 2 trial of PTX-100. Prescient has hitherto been focused on testing PTX 100 across all T cell lymphomas, namely cutaneous T cell lymphomas (CTCL) and peripheral T cell lymphomas (PTCL). Following extensive analysis and consultation Prescient has determined to focus its upcoming Phase 2 clinical trial on CTCL. Prescient maintains its interest in pursuing PTCL, with promising early data in this indication and Orphan Drug designation covering all TCLs.

CTCLs occur when a group of immune cells called T cells become cancerous and attack the skin. They are comprised of a range of different subtypes with differing characteristics, and can be either indolent or

aggressive. CTCL is an orphan disease with around 1000 new cases diagnosed in the US each year with this incidence increasing. Industry analysts predict that the market for CTCL therapies will grow to around US$750 million per year by 2032.

There are several reasons underpinning the strategy to focus the upcoming Phase 2 trial on CTCL, including:

- Confidence of PTX 100 in CTCL, given strong responders in this patient population.
- A greater need for new, safe and effective therapies. CTCLs is a largely unaddressed patient population regarding new therapy development. By contrast, whilst PTCL is more prevalent than CTCL it has more existing and emerging competition despite still being a poorly met clinical need.
- Potentially more efficient pathway for approval for CTCL.
- Potential advantages in patient recruitment (despite CTCL having a lower incidence than PTCL), because of less clinical trial competition for patients, and a larger patient pool because of high prevalence and longer patient life expectancy

Prescient continues with an ongoing interest in PTCL, and is optimistic about the potential for PTX-100 in this patient population. In parallel to the Phase 2 trial in CTCL, Prescient plans to use the current Phase 1b trial to obtain additional data in PTCL. If this is successful, the Company may move forward with a separate Phase 2 PTCL study. The Phase 1b study remains ongoing, with one patient still on study with a durable complete response.

Following the reporting period Prescient submitted a briefing document and questions to the FDA to inform the trial design and IND application and has received feedback from the FDA. FDA feedback on dose optimisation and additional nonclinical data on potential drug-drug interactions is readily addressable. The IND submission remains on track to be submitted before the end of 2024, with initial opening of the clinical trial in early 2025. Registration potential will be a matter of ongoing dialogue with the FDA.

Prescient's Chemistry, Manufacturing, and Control (CMC) activities to support PTX-100's development plans are on track and are not expected to impact the timing of the study.

Cell therapy platforms

Dr Mariam Mansour, Director of Clinical development and Translational Science, was invited to the CAR-TCR Summit in Boston last month to present CellPryme. Prescient was the only company presenting data on cell therapy manufacturing and adjuvant enhancements. Feedback from the CAR-TCR Summit

was very positive, generating productive discussions with commercial companies that are looking for practical ways to augment their cell therapy programs.

Prescient is progressing well in discussions with several potential partners regarding the evaluation of CellPryme-M. Although these evaluations take time, the Company is pleased to note that multiple discussions are moving forward concurrently.

Meanwhile, Prescient is producing additional clinical-grade CellPryme-A in preparation for its first-in-human clinical trials, which will assess its potential in combination with CAR-T therapies. Despite challenges within the cell therapy field, the Company remains committed to pursuing external opportunities to clinically validate CellPryme-A's role in enhancing cell therapies.

Summary

Prescient has a clear path to value creation with an initial focus on PTX-100 in CTCL, which the Company believes serves the greatest unmet need and presents the most efficient route to market in the event of success. After a productive FDA interaction, Prescient plans to submit the IND by the end of 2024, and initiation of patient enrolment to its Phase 2 clinical trial in early 2025.

Prescient also remains well-positioned to capitalise on a recovery in the cell therapy sector with platform technologies to enhance third-party cell therapy programs and drive future growth.

- Ends -

To stay updated with the latest company news and announcements, please update your details on our investor centre.

About Prescient Therapeutics Limited (Prescient)

Prescient Therapeutics (ASX: PTX) is a clinical stage oncology company developing personalised medicine approaches to cancer, including targeted and cellular therapies.

Targeted Therapy

PTX-100 is a first in class compound with the ability to block an important cancer growth enzyme known as geranylgeranyl transferase-1 (GGT-1). It disrupts oncogenic Ras pathways by inhibiting the activation of Rho, Rac and Ral circuits in cancer cells, leading to apoptosis (death) of cancer cells. PTX- 100 is believed to be the only GGT-1 inhibitor in the world in clinical development. PTX-100 demonstrated safety and early clinical activity in a previous Phase 1 study and recent PK/PD basket study of hematological and solid malignancies. PTX-100 is now in a Phase 1b expansion cohort study in T cell lymphomas, where it is showing encouraging efficacy and safety. The US FDA has granted PTX-100 Orphan Drug Designation for all T Cell Lymphomas. A Phase 2 study is in planning.

Cell Therapy Platforms

CellPryme-M: Prescient's novel, ready-for-the-clinic, CellPryme-M technology enhances adoptive cell therapy performance by shifting T towards a central memory phenotype, improving persistence, and increasing the ability to find and penetrate tumours. CellPryme-M is a 24-hour, non-disruptive process during cell manufacturing. Cell therapies that could benefit from additional productivity in manufacturing or increased potency and durability in-vivo, would be good candidates for CellPryme-M.

CellPryme-A: CellPryme-A is an adjuvant therapy designed to be administered to patients alongside cellular immunotherapy to help them overcome a suppressive tumour microenvironment. CellPryme-A significantly decreases suppressive regulatory T cells; increases expansion of CAR-T cells in vivo; increases tumour penetration of CAR-T cells. CellPryme-A improves tumour killing and host survival of CAR-T cell therapies, and these benefits are even greater when used in conjunction with CellPryme-M pre-treated CAR-T cells.

OmniCAR: is a universal immune receptor platform enabling controllable T-cell activity and multi- antigen targeting with a single cell product. OmniCAR's modular CAR system decouples antigen recognition from the T-cell signalling domain. It is the first universal immune receptor allowing post- translational covalent loading of binders to T-cells. OmniCAR is based on technology licensed from Penn; the SpyTag/SpyCatcher binding system licensed from Oxford University; and other assets. OmniCAR is in pre-clinical development.

The targeting ligand can be administered separately to CAR-T cells, creating on-demand T-cell activity post infusion and enables the CAR-T to be directed to an array of different tumour antigens. OmniCAR provides a method for single-vector, single cell product targeting of multiple antigens simultaneous or sequentially, whilst allowing continual re-arming to generate, regulate and diversify a sustained T-cell response over time.

Find out more at www.ptxtherapeutics.com or connect with us via Twitter @PTX_AUS and LinkedIn.

The Board of Prescient Therapeutics Limited has approved the release of this announcement.

For more information please contact:

Company enquiries
Steve Engle
Chair
Prescient Therapeutics
sengle@ptxtherapeutics.com

Steven Yatomi-Clarke
CEO & Managing Director
Prescient Therapeutics
steven@ptxtherapeutics.com

Investor enquiries
Christian Riedel
Reach Markets
1300 805 795
ir@reachmarkets.com.au

Disclaimer and Safe Harbor Statement

Certain statements made in this document are forward-looking statements within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These forward-looking statements are not historical facts but rather are based on the current expectations of Prescient Therapeutics Limited ("Prescient" or the "Company"), their estimates, assumptions, and projections about the industry in which Prescient operates. Material referred to in this document that use the words 'estimate', 'project', 'intend', 'expect', 'plan', 'believe', 'guidance', and similar expressions are intended to identify forward-looking statements and should be considered an at-risk statement. These forward-looking statements are not a guarantee of future performance and involve known and unknown risks and uncertainties, some of which are beyond the control of Prescient or which are difficult to predict, which could cause the actual results, performance, or achievements of Prescient to be materially different from those which may be expressed or implied by these statements. These statements are based on our management's current expectations and are subject to a number of uncertainties and risks that could change the results described in the forward-looking statements. Risks and uncertainties include, but are not limited to, general industry conditions and competition, general economic factors, global pandemics and related disruptions, the impact of pharmaceutical industry development and health care legislation in the United States and internationally, and challenges inherent in new product development. In particular, there are substantial risks in drug development including risks that studies fail to achieve an acceptable level of safety and/or efficacy. Investors should be aware that there are no assurances that results will not differ from those projected and Prescient cautions shareholders and prospective shareholders not to place undue reliance on these forward- looking statements, which reflect the view of Prescient only as of the date of this announcement. Prescient is not under a duty to update any forward-looking statement as a result of new information, future events or otherwise, except as required by law or by any appropriate regulatory authority.

Certain statements contained in this document, including, without limitation, statements containing the words "believes," "plans," "expects," "anticipates," and words of similar import, constitute "forward- looking statements." Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Prescient to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, the following: the risk that our clinical trials will be delayed and not completed on a timely basis; the risk that the results from the clinical trials are not as favourable as we anticipate; the risk that our clinical trials will be more costly than anticipated; and the risk that applicable regulatory authorities may ask for additional data, information or studies to be completed or provided prior to their approval of our products. Given these uncertainties, undue reliance should not be placed on such forward-looking statements. The Company disclaims any obligation to update any such factors or to publicly announce the results of any revisions to any of the forward-looking statements contained herein to reflect future events or developments except as required by law.

This document may not contain all the details and information necessary for you to make a decision or evaluation. Neither this document nor any of its contents may be used for any other purpose without the prior written consent of the Company.

Supplemental COVID-19 Risk Factors

Please see our website: Supplemental COVID-19 Risk Factors

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity	
Prescient Therapeutics Limited	
ABN	**Quarter ended ("current quarter")**
56 006 569 106	30 September 2024

Consolidated statement of cash flows		**Current quarter $A'000**	**Year to date (3 months) $A'000**
1.	**Cash flows from operating activities**		
1.1	Receipts from customers	-	-
1.2	Payments for		
	(a) research and development	(1,823)	(1,823)
	(b) product manufacturing and operating costs	-	-
	(c) advertising and marketing	-	-
	(d) leased assets	-	-
	(e) staff costs	(258)	(258)
	(f) administration and corporate costs	(868)	(868)
1.3	Dividends received (see note 3)	-	-
1.4	Interest received	141	141
1.5	Interest and other costs of finance paid	(6)	(6)
1.6	Income taxes paid	-	-
1.7	Government grants and tax incentives	-	-
1.8	Other (provide details if material)	-	-
1.9	**Net cash from / (used in) operating activities**	**(2,814)**	**(2,814)**

2.	**Cash flows from investing activities**		
2.1	Payments to acquire or for:		
	(g) entities	-	-
	(h) businesses	-	-
	(i) property, plant and equipment	-	-

Consolidated statement of cash flows		Current quarter $A'000	Year to date (3 months) $A'000
	(j) investments in term deposits with maturities longer than 3 months at acquisition	-	-
	(k) intellectual property	-	-
	(l) other non-current assets	-	-
2.2	Proceeds from disposal of:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
2.6	**Net cash from / (used in) investing activities**	**-**	**-**

3.	**Cash flows from financing activities**		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	-	-
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	-	-
3.4	Transaction costs related to issues of equity securities or convertible debt securities	-	-
3.5	Proceeds from borrowings	-	-
3.6	Repayment of borrowings	(193)	(193)
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (provide details if material)	-	-
3.10	**Net cash from / (used in) financing activities**	**(193)**	**(193)**

Consolidated statement of cash flows		Current quarter $A'000	Year to date (3 months) $A'000
4.	**Net increase / (decrease) in cash and cash equivalents for the period**		
4.1	Cash and cash equivalents at beginning of period	10,492	10,492
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(2,814)	(2,814)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	-	-
4.4	Net cash from / (used in) financing activities (item 3.10 above)	(193)	(193)
4.5	Effect of movement in exchange rates on cash held	(14)	(14)
4.6	**Cash and cash equivalents at end of period**	***7,471**	***7,471**

** In addition to the cash and cash equivalents balance above as at 30 September 2024, the Company holds an additional $4 million in term deposits with maturity terms greater than 3 months (30 June 2024: $4 million), classified in the statement of financial position as short-term investments in accordance with AASB.*

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter $A'000	Previous quarter $A'000
5.1	Bank balances	1,471	4,492
5.2	Call deposits*	6,000	6,000
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
5.5	**Cash and cash equivalents at end of quarter (should equal item 4.6 above)**	****7,471**	****10,492**

**The call deposits included in item 5.2 above, have maturities ranged between 1 month and 3 months at 30 September 2024.*

*** In addition to the cash and cash equivalents balance above as at 30 September 2024, the Company holds an additional $4 million in term deposits with maturity terms greater than 3 months (30 June 2024: $4 million), classified in the statement of financial position as short-term investments in accordance with AASB.*

6.	Payments to related parties of the entity and their associates	Current quarter $A'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	194
6.2	Aggregate amount of payments to related parties and their associates included in item 2	-

Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.

7.	Financing facilities *Note: the term "facility' includes all forms of financing arrangements available to the entity.* *Add notes as necessary for an understanding of the sources of finance available to the entity.*	Total facility amount at quarter end $A'000	Amount drawn at quarter end $A'000
7.1	Loan facilities	-	-
7.2	Credit standby arrangements	-	-
7.3	Other (Premium financing)	137	137
7.4	**Total financing facilities**	**137**	**137**

7.5	**Unused financing facilities available at quarter end**	-
7.6	Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.	

Financier: Clearmatch Originate Pty Limited
Interest rate: 3.09%
Maturity date: 25 January 2025
Secured by the underlying insurance policies

8.	Estimated cash available for future operating activities	$A'000
8.1	Net cash from / (used in) operating activities (item 1.9)	(2,814)
8.2	Cash and cash equivalents at quarter end (item 4.6)	7,471
8.3	Unused finance facilities available at quarter end (item 7.5)	-
8.4	Total available funding (item 8.2 + item 8.3)	*7,471
8.5	**Estimated quarters of funding available (item 8.4 divided by item 8.1)**	***2.7**

Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.

** In addition to the cash and cash equivalents balance noted above at 8.4, the Company holds an additional $4 million in term deposits, classified in the statement of financial position as short-term investments in accordance with AASB, due to the maturity date being greater than 3 months. As a result, the estimated quarters of funding available will be greater than the figure provided in 8.5 due to holding these additional short-term investments. On a pro-forma basis with the $4 million included, the Company would have estimated quarters of funding available amounting to 4.1.*

8.6	If item 8.5 is less than 2 quarters, please provide answers to the following questions: N/A
	8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?
	N/A
	8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?
	N/A
	8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?
	N/A
	Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.

Compliance statement

1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.

2 This statement gives a true and fair view of the matters disclosed.

Date: 31 October 2024

Authorised by: By the Board
(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.

2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.

3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.

4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [*name of board committee – eg Audit and Risk Committee*]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".

5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.